Q-omics provides the consensus-scored MIR4290HG profile across patient tissues and cancer cell-line models. MIR4290HG expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR4290HG is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, MIR4290HG RNA expression shows 6,461 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, BRCA, and STAD as cancer lineages where MIR4290HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4290HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4290HG survival associations across molecular data types. MIR4290HG RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4290HG RNA expression–survival associations across cancer types. High MIR4290HG expression shows unfavorable associations in PCPG, CHOL, ESCA and SKCM, but favorable associations in KICH and LGG. The KICH Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for MIR4290HG RNA expression.
This table summarizes MIR4290HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4290HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4290HG shows lower tumor expression in KIRC, LIHC, CHOL and COAD and higher tumor expression in BRCA and KICH. The BRCA box plot shows higher MIR4290HG RNA expression in tumor versus normal tissue (log2 FC = +0.019, t-test p = .037).
This table shows molecular features associated with MIR4290HG in patient tissues and cancer cell lines. In patient samples, MIR4290HG shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
